AEON Biopharma, Inc. — Form 10-Q
Filed August 12, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 2/100
What the filing says
Robert Bancroft (President/CEO) and John Bencich (CFO) issued standard SOX 302 and 906 certifications dated August 12, 2026 for the quarterly report ended June 30, 2026. Both officers certified the financial statements fairly present the company's condition and that disclosure controls and internal controls over financial reporting are effective. No material weaknesses, deficiencies, or fraud were disclosed.
Why this rating
Boilerplate SOX compliance certifications; no operational, financial, or strategic changes disclosed. Routine periodic filing requirement.
See more from August 12, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.